Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 60

Posts Tagged ‘patents’

DFLabs Awarded with Two U.S. Patents for Its Pioneering SOAR Technology

Posted by fidest press agency su venerdì, 11 ottobre 2019

DFLabs, the award-winning Security Orchestration, Automation and Response (SOAR) vendor, today announced it has been awarded two patents by the United States Patent and Trademark Office (USPTO) related to its IncMan SOAR platform. The patents recognize innovative methods for Incident Correlation and Visualization, and its Machine Learning Method for Playbook Automation. DFLabs’ patented Incident Correlation and Visualization correlates critical incident attributes, enabling analysts to uncover patterns and detect hidden threats among the massive amount of intelligence gathered by IncMan SOAR on a daily basis. Correlation data is presented to the analyst in an easy to use, interactive user interface, allowing users to quickly visualize complex relationships between any number of unique artifacts. Unique among SOAR vendors, Incident Correlation and Visualization empowers security operations teams to perform threat hunting on a whole new level.
DFLabs’ patented Machine Learning Method for Playbook Automation incorporates granular user feedback into an advanced machine learning system. This one-of-a-kind capability learns based on responses to previous incidents and is able to recommend and apply the Playbooks which are most appropriate to respond to a new incident. The manner in which this machine learning is applied allows IncMan SOAR to detect similarities in an incident which may go unnoticed by analysts, immediately increasing the effectiveness of the response, especially for less experienced analysts.
“Most cybersecurity environments are bombarded with an overwhelming number of alerts. IncMan SOAR helps to identify actual attacks and improve response times by up to 80%, while improving team productivity tenfold,“ said Michele Zambelli, CTO at DFLabs. “Our Product roadmap is very aggressive for the next two years and we envision great adoption both from enterprises and MSSPs alike.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

ROMEG Therapeutics Secures Two Additional U.S. Patents

Posted by fidest press agency su venerdì, 23 agosto 2019

ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the formulation, methods of use and administration of ROMEG’s proprietary colchicine oral solution, which will be marketed as GLOPERBA® and is currently indicated for prophylaxis of gout flares in adults.U.S. patent numbers 10,383,820 and 10,383,821 are the third and fourth patents ROMEG has been granted for its colchicine oral solution and will join the first two patents already listed in the U.S. Food and Drug Administration’s Orange Book, the guide to drugs classified by the agency as safe and effective and that are protected by a patent. Specifically, the two patents will broaden the composition claims of the colchicine oral solutions and cover methods to potentially enable additional indications.“We are extremely pleased with the continued development of our patent portfolio, as it reflects our strategy to broaden and diversify our intellectual property,” said Naomi Vishnupad, Ph.D., ROMEG’s Chief Scientific Officer and a partner in the company. “In this case, we believe our product technology offers a novel and potentially superior treatment option for diseases such as gout and other diseases that represent significant unmet medical needs and a large market opportunity.” GLOPERBA®, approved by the FDA earlier this year, was recently licensed to Avion Pharmaceuticals, LLC of Alpharetta, Ga., for exclusive commercialization within the United States. The current U.S. market for gout is about $650 million annually.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

SpinalCyte Announces New International Patents

Posted by fidest press agency su venerdì, 9 novembre 2018

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of new patents in Hong Kong and Europe. The company’s industry leading intellectual property in spine treatments now includes 35 U.S. and foreign patents issued with 41 patents pending, which provide a commanding intellectual property estate for its lead product, CybroCell™. The company’s positive results from its completed clinical trial and strong patent portfolio continue to spur interest among biotech investors for licensing and partnership opportunities.“These new patents add to our extensive portfolio and bolster the international protections for our fibroblast technology,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “SpinalCyte is at the forefront of human dermal fibroblast cell therapy, specifically in disc degeneration. We hold all intellectual property related to HDF treatment for degenerative disc disease (DDD), positioning us as the front-runner in this emerging sector of cell therapies.”The technologies described in Hong Kong Patent No. HK1197832, “Dermal Fibroblasts for Treatment of Degenerative Disc Disease,” and European Patent No. 3146939, “Composition for Repair of Cartilage Using an In Vivo Bioreactor,” related to generating chondrocyte-like cells and applying them within the spinal disc space. Additional claims surround the paracrine benefit of introducing fibroblasts to the disc environment.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Carestream’s Successful R&D Efforts Earn 36 U.S. Patents In 2017; 43 Additional Patents in Other Countries

Posted by fidest press agency su giovedì, 25 gennaio 2018

CarestreamCarestream Health was awarded 36 new patents from the U.S. Patent and Trademark Office last year for innovation in radiography; cone beam CT imaging; healthcare IT; and other areas. The company also received 43 additional patents in European and Asian countries last year.New medical image capture technologies related to the development of cone beam computed tomography (CT) systems designed for orthopaedic extremity imaging
Enhancements to Carestream’s portfolio of healthcare IT systems that manage, store and share patient data and medical imaging exams
Continued technology advances in Carestream’s growing portfolio of radiology systems that can enhance diagnostic image quality for a wide range of healthcare providers; and
Advancements in Carestream laser imagers that provide affordable output of digital X-ray exams onto medical film and paper.
The company’s product portfolio includes digital imaging systems for general radiology and specialty areas such as orthopaedics and pediatrics; digital laser imagers that output medical images to film and paper; and the latest healthcare IT solutions and cloud-based services for hospitals, clinics and physician practices. (photo: Carestream)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »